Skip to content


Open Access

The pharmacotherapy of depression with EPA

  • Basant K Puri1
Annals of General Psychiatry20109(Suppl 1):S23

Published: 22 April 2010


Public HealthMarked DecreaseVentricular VolumeEpidemiological EvidenceBiochemical Evidence

This lecture considers the pharmacotherapy of depression with EPA under the following headings:

  • Epidemiological evidence

  • Biochemical evidence

  • First trial of pure EPA in severe treatment-resistant depression

  • Subsequent randomized double-blind placebo-controlled trials

  • Putative mechanisms.

Results obtained from our own group, including structural neuroimaging and 31-phosphorus neurospectroscopy findings, showing an association of EPA treatment of depression with a marked decrease in cerebral phosphodiesters, a marked increase in cerebral phosphomonoesters and reduced lateral ventricular volume, will also be presented.

Authors’ Affiliations

Imperial College London, UK


© Puri; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd.